Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus FORTAZ.
CEFTAZIDIME IN DEXTROSE CONTAINER vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g intravenously every 8 hours.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic